"Clinical presentation "
"General "
"Clinical course is often very aggressive with poor response to conventional chemotherapy. Poor survival rates have usually been reported with the potential long-term curative treatment being haematopoietic stem cell transplantation. Treatment with purine analogues and alemtuzumab have been reported to have significantly higher response rates and improved survival 2,3."
"In the WHO classification, this is referred to as T-prolymphocytic leukaemia rather than T-cell prolymphocytic leukaemia."
"In the WHO classification, this is referred to as T-prolymphocytic leukaemia rather than T-cell prolymphocytic leukaemia."
Expected headings
"Clinical presentation "
"General "
"It is characterised by the proliferation of small- to medium-sized prolymphocytes of post-thymic origin. Many tissues can be involved, including peripheral blood, bone marrow, lymph nodes, liver, spleen, and skin."